ACE-031
ACE-031
Half-life
12 days
Time to Peak
3 days
Steady State
~60 days
Dose Range
0.5–3 mg/kg
Frequency
Every 2 weeks
Overview
Soluble form of activin receptor type IIB (ActRIIB) fused to the Fc portion of human IgG1. Acts as a decoy receptor, trapping myostatin and other TGF-beta superfamily ligands before they can bind cell-surface receptors. Developed by Acceleron Pharma for Duchenne muscular dystrophy. DISCONTINUED after Phase II due to safety signals (epistaxis, telangiectasias — likely from trapping BMP9/10 which regulate vascular integrity). Successor program (ACE-083, local myostatin trap) also discontinued. Included for historical reference — some community interest persists.
Mechanism of Action
Soluble ActRIIB-Fc fusion protein. Sequesters myostatin, activin A, GDF-11, and other TGF-beta superfamily ligands in the circulation, preventing them from binding cell-surface ActRIIB and inhibiting muscle growth.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Subcutaneous (SubQ) | 0.5–3 mg/kg | 12 days | 3 days | Every 2 weeks |
Storage & Handling
2-8C — Refrigerate. Do not freeze. Protect from light.
Used in Regimens
ACE-031 is not currently part of any catalog regimen.
Related Tools
Track ACE-031 with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.